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Abstract
Background: Medullary thyroid carcinoma accounts for approximately 1 to 2 % of all thyroid carcinoma cases.
The most common route of dissemination is to locoregional lymph nodes. Distant metastases commonly affect bones,
lungs, and liver. We present a case of a white woman with a 25-year history of medullary thyroid carcinoma
on multiple medications including tyrosine kinase inhibitor therapy for the last 11 months, who exhibited
unusual diffuse infiltration of advanced stage medullary thyroid carcinoma to her gastric mucosa.
Case presentation: A 53-year-old white woman presented with increasing fatigue, loss of appetite, and
severe epigastric pain radiating to her back. She had a history of medullary thyroid carcinoma (pT2pN1b),
diagnosed 25 years ago and treated by complete thyroidectomy and repeated bilateral cervical lymph node
dissection. Medical therapy included octreotide 20 mg every 4 weeks, which was switched to the tyrosine
kinase inhibitor vandetanib 300 mg/day 11 months ago when computed tomography scanning revealed
progressive mediastinal lymph node and diffuse and symptomatic pulmonary metastases. Of note, she demonstrated
macroscopically stable pulmonary and mediastinal lymph node metastases; however, her calcitonin serum levels
dramatically increased. Computed tomography scanning revealed a single new intrahepatic lesion (4 mm) as well as
multiple (>10) new supraclavicular lesions suggestive of medullary thyroid carcinoma progress. As proven by gastric
biopsy and immunohistochemical evaluation, her epigastric pain was explained by a diffuse infiltration of her gastric
mucosa by metastatic medullary thyroid carcinoma. Subsequently, she rapidly deteriorated and died.
Conclusions: The current case report shows for the first time an unusual metastatic infiltration of the gastric mucosa
by medullary thyroid carcinoma. When treating these patients, it is important to include this differential diagnosis
during follow-up.
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Background
Thyroid cancer overall represents a rare tumor entity,
however, the incidence of thyroid cancer has recently been
constantly increasing [1, 2]. Within this heterogeneous
group of tumors, differentiated thyroid cancer represents
the majority (approximately 90 %) of all newly diagnosed
thyroid cancer cases [3]. Medullary thyroid carcinoma
(MTC) accounts for approximately 1 to 2 % of all thyroid
carcinoma cases, and at diagnosis 7 to 23 % of all patients
demonstrate metastatic disease [1, 4]. Overall, 10-year
disease-specific survival rates average approximately 75 %
with a strong dependency on tumor stage (averaging
21 % in stage IV tumors). Metastases are commonly
found in the lymph nodes, while distant metastatic
disease is found in lungs, bone, and liver, and, more
rarely, in brain, skin, and breast [5, 6]. Therapeutic-
ally, the recent introduction of tyrosine kinase inhibi-
tor therapy (vandetanib, cabozantinib) has led to a
significant improvement of the prognosis in patients
with rapidly progressive and advanced stage MTC [7].
Case presentation
A 53-year-old white woman presented with increasing
fatigue, loss of appetite, and severe epigastric pain radiat-
ing to her back. She had a history of MTC (pT2pN1b),
diagnosed 25 years ago and treated by complete
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thyroidectomy and bilateral cervical lymph node dissec-
tion, followed by repeated surgical resection of lymph
node metastases 19 and 12 years ago. No further specific
treatment modalities (for example radiotherapy) had
been employed. No genetic analysis had been performed
for germline or somatic RET proto-oncogene mutations,
nor for other somatic mutations (HRAS, KRAS, NRAS).
On clinical examination, however, there was no indica-
tion of other manifestations of multiple endocrine neo-
plasia type 2 (MEN2), especially no clinical signs of
pheochromocytoma. Since data on the RET proto-
oncogene status have been missing in our patient, no
risk category (moderate, high, highest) according to the
revised American Thyroid Association Guidelines for
the management of MTC [1] had been assigned. How-
ever, based on the American Joint Committee on Cancer
(AJCC) TNM-Classification, the MTC had been a stage
IV A tumor (pT2pN1b) at the time of the initial complete
thyroidectomy in our patient. Post complete thyroidec-
tomy, she had hypoparathyroidism, which was treated
with calcium and calcitriol. She received levothyroxine re-
placement therapy. Repeated biochemical and clinical
evaluations during the course of the disease did not dem-
onstrate any signs of paraneoplastic adrenocorticotropic
hormone (ACTH) and/or corticotropin-releasing hor-
mone (CRH) secretion. Medical therapy of the MTC in-
cluded octreotide 20 mg every 4 weeks, which was
switched to the tyrosine kinase inhibitor vandetanib 300
mg/day 11 month ago when computed tomography (CT)
scanning revealed progressive mediastinal lymph node
and diffuse and symptomatic pulmonary metastases.
Standard laboratory tests in our patient revealed mod-
erate leukocytosis (18.3 G/l) as well as slightly elevated
serum CRP levels (12.58 mg/l); her serum lactate was
5.5 mmol/l. Pancreatitis was ruled out because her
serum amylase and lipase levels were within normal
range. An upper endoscopy was performed and demon-
strated multiple centrally ulcerated lesions in her gastric
mucosa of up to 4 mm in size (Fig. 1a, b). Two-phase
contrast-enhanced multi-detector CT of her chest and
abdomen revealed stable pulmonary and mediastinal
lymph node metastases; however, there was a single new
intrahepatic lesion of 4 mm size suspicious for liver me-
tastasis. Contrast-enhanced multi-detector CT of her
neck revealed multiple, new, centrally hypodense supra-
clavicular lesions up to 12 mm in size suggestive of
lymph node metastases. In addition, multiple noduli
within her stomach wall were apparent (Fig. 1c, I–III).
Three-phase bone scintigraphy showed no evidence of
bone metastasis.
Additional laboratory tests revealed a dramatic in-
crease in her basal serum calcitonin levels from 563 pg/
ml to 6487 pg/ml within 2 months, indicative of rapid
tumor progress of the underlying MTC. Of interest, at
the same time she had rather stable carcinoembryonic
antigen (CEA) serum levels of 40.7 ng/ml (from 62.3
ng/ml 14 months earlier). Histologic and immunohis-
tochemical analyses of gastric biopsy specimen dem-
onstrated diffuse mucosal infiltration of MTC
(Fig. 1d–h) with a KI-67 index of up to 40 %, proving
metastatic disease of MTC to the gastric mucosa. Of
note, while immunohistochemical analysis of calci-
tonin was strongly positive (Fig. 1g), staining for CEA
demonstrated merely focal and weak staining (Fig. 1h);
staining for thyroglobulin remained completely nega-
tive (data provided in Additional file 1). She rapidly
deteriorated and died due to multiorgan failure before
third-line treatment could be initiated.
Conclusions
MTC is sporadic in origin in 60 to 75 % of all
patients with MTC, while the others exhibit germline
mutations in the RET proto-oncogene, namely
patients with multiple endocrine neoplasia type 2A
(MEN2A), multiple endocrine neoplasia type 2B
(MEN2B), and familial MTC syndrome (FMTC). The
most common sites for metastatic disease in MTC
are locoregional lymph nodes; these metastases often
occur early in the disease process [8]. This was also
the case in our patient, who initially presented with a
pT2pN1b tumor stage, and who received repeated re-
section of cervical lymph node metastases during the
following years.
However, in advanced MTC, distant metastases have
been described. In one report, 74 % of patients demon-
strated metastatic disease to the bone [9], other groups
found small hepatic metastases in 25 % of patients with
advanced MTC [10], as well as lung metastases in 35 %
of patients with MTC with persistently elevated calci-
tonin levels after initial treatment [5]. In addition, cases
of cutaneous [11, 12], brain [13], and breast [14, 15]
metastases of MTC have been described.
Metastatic disease to the stomach overall is a rare
incidence in all cancer types, and data in the litera-
ture are based on case reports as well as small case
series [16–18]. The most common primary tumors re-
ported to spread to the stomach are melanoma,
breast, lung, and esophageal carcinoma as well as
renal cell cancer [17]. On clinical examination, gastric
metastases present with epigastric pain, nausea,
vomiting, as well as gastrointestinal hemorrhage.
Mostly solitary lesions within the gastric mucosa are
observed, although multiple metastatic lesions have
been reported as well [17]. To the best of our know-
ledge, metastatic disease to the gastric mucosa of a
MTC has not yet been reported in the literature.
Our patient had MTC with a follow-up history of 25
years and presented with severe epigastric pain. Multiple
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lesions within her gastric mucosa were histologically
proved to be a diffuse metastatic infiltration of the
MTC. Of note, CT scans of her chest and abdomen re-
vealed stable pulmonary and mediastinal lymph node
metastases; however, multiple supraclavicular lesions as
well as a single new intrahepatic lesion were suggestive
of MTC progress. Remarkably, a sharp rise in calcitonin
levels was indicative of rapid tumor progression as well,
while her serum levels of CEA remained rather stable.
The current case report should raise awareness of
unusual gastrointestinal metastatic disease of MTC in
advanced disease states, especially with the increasing
prognosis of these tumors due to molecular-targeted
oncologic therapies (for example tyrosine kinase inhibi-
tors). In treating these patients, it is important to include
this generally uncommon differential diagnosis for
unspecific patient complaints during follow-up.
Additional file
Additional file 1: Immunohistochemical staining of gastric biopsy
specimen for thyroglobulin remained completely negative. (TIF 1120 kb)
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Fig. 1 a, b Endoscopic view of the gastric corpus mucosa. c Computed tomography demonstrating multiple small noduli within the stomach
wall: I overview, noduli marked by white circle; II, III magnification, noduli marked by white arrows. d–h Histologic and immunohistochemical
staining of gastric biopsy specimen. d Hematoxylin-eosin, overview. e Hematoxylin-eosin, detail. f Immunohistochemical staining for chromogranin A.
g Immunohistochemical staining for calcitonin. h Immunohistochemical staining for carcinoembryonic antigen (CEA). Remarkably, histology reveals
intact non-neoplastic gastric gland structures (marked by *) in between infiltrating cells
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